Abstract
Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have